CONMED Historical Income Statement

CNMD Stock

USD 73.16 0.73 0.99%

Historical analysis of CONMED income statement accounts such as Interest Expense of 41.8 M, Selling General Administrative of 531.1 M or Total Revenue of 1.3 B can show how well CONMED performed in making a profits. Evaluating CONMED income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CONMED's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining CONMED latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CONMED is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.

About CONMED Income Statement Analysis

CONMED Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CONMED shareholders. The income statement also shows CONMED investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

CONMED Income Statement Chart

At present, CONMED's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 1.3 B, whereas Total Other Income Expense Net is projected to grow to (47.5 M).

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Net Interest Income

Total Revenue

Total revenue comprises all receipts CONMED generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of CONMED minus its cost of goods sold. It is profit before CONMED operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CONMED. It is also known as CONMED overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most accounts from CONMED's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CONMED current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.At present, CONMED's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 1.3 B, whereas Total Other Income Expense Net is projected to grow to (47.5 M).

	2021	2022	2023	2024 (projected)
Gross Profit	568.0M	571.2M	643.1M	675.2M
Total Revenue	1.0B	1.0B	1.2B	1.3B

Gross Profit Total Revenue

CONMED income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		0.42	0.6	0.57	0.61	0.6	0.0	0.01	0.28	0.53	0.6	0.08	0.05	0.13	-0.12	0.79	0.14	0.21	0.08	-0.16	0.28	-0.26	0.21	-0.33	0.21
Interest Expense	0.42		0.77	0.75	0.76	0.75	0.18	0.29	0.43	0.73	0.76	0.13	-0.28	0.15	-0.04	0.73	0.13	-0.47	-0.49	-0.63	0.97	-0.97	0.95	-0.9	-0.47
Selling General Administrative	0.6	0.77		0.99	0.99	1.0	0.58	0.43	0.62	0.99	1.0	0.27	-0.41	0.22	0.22	0.82	0.19	-0.55	-0.62	-0.58	0.77	-0.67	0.7	-0.68	-0.55
Total Revenue	0.57	0.75	0.99		1.0	1.0	0.61	0.5	0.67	1.0	1.0	0.32	-0.4	0.26	0.28	0.8	0.23	-0.58	-0.61	-0.56	0.75	-0.66	0.7	-0.67	-0.58
Gross Profit	0.61	0.76	0.99	1.0		1.0	0.58	0.46	0.65	0.98	1.0	0.31	-0.4	0.25	0.27	0.83	0.22	-0.53	-0.59	-0.53	0.75	-0.66	0.7	-0.69	-0.53
Other Operating Expenses	0.6	0.75	1.0	1.0	1.0		0.59	0.46	0.65	0.99	1.0	0.29	-0.4	0.23	0.25	0.81	0.2	-0.55	-0.6	-0.56	0.74	-0.65	0.69	-0.66	-0.55
Operating Income	0.0	0.18	0.58	0.61	0.58	0.59		0.53	0.54	0.64	0.59	0.5	-0.26	0.36	0.55	0.25	0.32	-0.73	-0.71	-0.46	0.3	-0.13	0.22	-0.24	-0.73
Ebit	0.01	0.29	0.43	0.5	0.46	0.46	0.53		0.96	0.53	0.44	0.83	0.07	0.81	0.28	0.17	0.78	-0.63	-0.14	-0.47	0.26	-0.3	0.27	-0.22	-0.63
Ebitda	0.28	0.43	0.62	0.67	0.65	0.65	0.54	0.96		0.69	0.63	0.81	0.06	0.8	0.25	0.38	0.78	-0.6	-0.15	-0.53	0.37	-0.39	0.36	-0.33	-0.6
Cost Of Revenue	0.53	0.73	0.99	1.0	0.98	0.99	0.64	0.53	0.69		0.99	0.34	-0.4	0.28	0.29	0.77	0.24	-0.63	-0.64	-0.59	0.73	-0.65	0.69	-0.64	-0.63
Total Operating Expenses	0.6	0.76	1.0	1.0	1.0	1.0	0.59	0.44	0.63	0.99		0.28	-0.4	0.23	0.24	0.82	0.2	-0.55	-0.61	-0.57	0.76	-0.66	0.7	-0.68	-0.55
Income Before Tax	0.08	0.13	0.27	0.32	0.31	0.29	0.5	0.83	0.81	0.34	0.28		0.51	0.95	0.4	0.04	0.95	-0.48	0.09	-0.31	0.08	-0.15	0.1	-0.06	-0.48
Total Other Income Expense Net	0.05	-0.28	-0.41	-0.4	-0.4	-0.4	-0.26	0.07	0.06	-0.4	-0.4	0.51		0.57	-0.02	-0.38	0.59	0.19	0.7	0.14	-0.41	0.23	-0.36	0.4	0.19
Net Income	0.13	0.15	0.22	0.26	0.25	0.23	0.36	0.81	0.8	0.28	0.23	0.95	0.57		0.11	0.02	1.0	-0.41	0.2	-0.43	0.07	-0.15	0.07	-0.02	-0.41
Income Tax Expense	-0.12	-0.04	0.22	0.28	0.27	0.25	0.55	0.28	0.25	0.29	0.24	0.4	-0.02	0.11		0.07	0.09	-0.33	-0.31	0.3	0.05	-0.03	0.13	-0.15	-0.33
Research Development	0.79	0.73	0.82	0.8	0.83	0.81	0.25	0.17	0.38	0.77	0.82	0.04	-0.38	0.02	0.07		0.01	-0.09	-0.4	-0.34	0.69	-0.62	0.62	-0.73	-0.09
Net Income From Continuing Ops	0.14	0.13	0.19	0.23	0.22	0.2	0.32	0.78	0.78	0.24	0.2	0.95	0.59	1.0	0.09	0.01		-0.36	0.25	-0.39	0.04	-0.12	0.03	0.01	-0.36
Non Recurring	0.21	-0.47	-0.55	-0.58	-0.53	-0.55	-0.73	-0.63	-0.6	-0.63	-0.55	-0.48	0.19	-0.41	-0.33	-0.09	-0.36		0.69	0.69	-0.55	0.5	-0.55	0.4	1.0
Non Operating Income Net Other	0.08	-0.49	-0.62	-0.61	-0.59	-0.6	-0.71	-0.14	-0.15	-0.64	-0.61	0.09	0.7	0.2	-0.31	-0.4	0.25	0.69		0.52	-0.65	0.48	-0.59	0.54	0.69
Tax Provision	-0.16	-0.63	-0.58	-0.56	-0.53	-0.56	-0.46	-0.47	-0.53	-0.59	-0.57	-0.31	0.14	-0.43	0.3	-0.34	-0.39	0.69	0.52		-0.62	0.57	-0.52	0.39	0.69
Interest Income	0.28	0.97	0.77	0.75	0.75	0.74	0.3	0.26	0.37	0.73	0.76	0.08	-0.41	0.07	0.05	0.69	0.04	-0.55	-0.65	-0.62		-0.95	0.97	-0.92	-0.55
Net Interest Income	-0.26	-0.97	-0.67	-0.66	-0.66	-0.65	-0.13	-0.3	-0.39	-0.65	-0.66	-0.15	0.23	-0.15	-0.03	-0.62	-0.12	0.5	0.48	0.57	-0.95		-0.98	0.88	0.5
Reconciled Depreciation	0.21	0.95	0.7	0.7	0.7	0.69	0.22	0.27	0.36	0.69	0.7	0.1	-0.36	0.07	0.13	0.62	0.03	-0.55	-0.59	-0.52	0.97	-0.98		-0.91	-0.55
Extraordinary Items	-0.33	-0.9	-0.68	-0.67	-0.69	-0.66	-0.24	-0.22	-0.33	-0.64	-0.68	-0.06	0.4	-0.02	-0.15	-0.73	0.01	0.4	0.54	0.39	-0.92	0.88	-0.91		0.4
Selling And Marketing Expenses	0.21	-0.47	-0.55	-0.58	-0.53	-0.55	-0.73	-0.63	-0.6	-0.63	-0.55	-0.48	0.19	-0.41	-0.33	-0.09	-0.36	1.0	0.69	0.69	-0.55	0.5	-0.55	0.4

Click cells to compare fundamentals

CONMED Account Relationship Matchups

CONMED income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	72.3M	52.2M	49.8M	49.8M	51.4M	31.9M
Interest Expense	42.7M	44.1M	35.5M	28.9M	39.8M	41.8M
Selling General Administrative	400.1M	373.8M	414.8M	454.0M	505.8M	531.1M
Total Revenue	955.1M	862.5M	1.0B	1.0B	1.2B	1.3B
Gross Profit	524.7M	460.3M	568.0M	571.2M	643.1M	675.2M
Other Operating Expenses	876.0M	816.4M	900.9M	975.4M	1.1B	1.2B
Operating Income	1.6M	(27.0M)	37.8M	70.1M	130.8M	137.3M
Ebit	1.6M	61.3M	108.6M	(42.0M)	130.8M	137.3M
Ebitda	73.9M	113.6M	158.4M	7.8M	182.2M	191.3M
Cost Of Revenue	430.4M	402.2M	442.6M	474.2M	597.9M	627.8M
Total Operating Expenses	445.6M	414.3M	458.3M	501.2M	564.2M	592.5M
Income Before Tax	31.2M	1.6M	73.1M	(70.9M)	80.8M	84.9M
Total Other Income Expense Net	29.6M	(44.4M)	(36.6M)	(140.9M)	(50.0M)	(47.5M)
Net Income	28.6M	9.5M	62.5M	(80.6M)	64.5M	67.7M
Income Tax Expense	2.6M	(7.9M)	10.6M	9.7M	16.4M	17.2M
Research Development	45.5M	40.5M	43.6M	47.2M	52.6M	28.4M
Net Income Applicable To Common Shares	28.6M	9.5M	62.5M	(80.6M)	(72.5M)	(68.9M)
Net Income From Continuing Ops	28.6M	9.5M	62.5M	(80.6M)	58.0M	60.9M
Tax Provision	2.6M	(7.9M)	10.6M	9.7M	(28.4M)	(26.9M)
Net Interest Income	(42.7M)	(44.1M)	(35.5M)	(28.9M)	(39.7M)	(41.7M)
Reconciled Depreciation	72.3M	72.6M	70.7M	69.5M	71.6M	75.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:

How To Invest In CONMED

Details

Is CONMED Stock a good investment?

Details

What is CONMED's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

2.14

Dividend Share

0.8

Earnings Share

4.22

Revenue Per Share

41.821

Quarterly Revenue Growth

0.04

The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CONMED Historical Income Statement

About CONMED Income Statement Analysis

CONMED Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Net Interest Income

CONMED income statement Correlations

CONMED Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CONMED income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Gross Profit	+ 1.0	Total Revenue
Other Operating Expenses	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Total Revenue

Reconciled Depreciation	- 0.98	Net Interest Income
Net Interest Income	- 0.97	Interest Expense
Net Interest Income	- 0.95	Interest Income
Extraordinary Items	- 0.92	Interest Income
Extraordinary Items	- 0.91	Reconciled Depreciation
Extraordinary Items	- 0.9	Interest Expense